Back to Journals » OncoTargets and Therapy » Volume 9

Impact of diabetes mellitus on the survival of pancreatic cancer: a meta-analysis

Authors Shen H, Zhan M, Wang W, Yang D, Wang J

Received 4 September 2015

Accepted for publication 11 December 2015

Published 22 March 2016 Volume 2016:9 Pages 1679—1688

DOI https://doi.org/10.2147/OTT.S95744

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Ram Prasad

Peer reviewer comments 3

Editor who approved publication: Professor Barbara Burtness


Hui Shen, Ming Zhan, Wei Wang, Dong Yang, Jian Wang

Department of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China

Background: Diabetes mellitus (DM) is a risk factor for pancreatic cancer (PC), but its prognostic value in PC is still unclear. To elucidate this issue, we systematically reviewed the evidence concerning the association between diabetes status and PC.
Methods: Medline and EMBASE databases were searched to identify the eligible studies. Overall and subgroup analyses were performed to detect the discrepancy of prognosis according to diabetes status. Hazard ratios (HRs) with 95% CI were used to estimate the effect size.
Results: Eighteen studies including 16,181 patients with sample size ranging from 113 to 4,658 were pooled in this meta-analysis. Results showed that patients with DM had worse survival (HR 1.19, 95% CI: 1.07–1.32). In view of the impact of diabetes duration and tumor stage on the outcomes, we classified the studies into different groups. The results indicated that DM was associated with survival in both long-standing diabetes (HR 1.26, 95% CI: 1.14–1.40) and recent-onset diabetes (HR 1.29, 95% CI: 1.09–1.51). Data regarding localized disease (HR 1.57, 95% CI: 1.00–2.46) and nonlocalized (locally advanced and metastatic) disease (HR 1.42, 95% CI: 1.16–1.73) verified that the prognostic value was independent of tumor stage.
Conclusion: Our results suggested that patients with DM were associated with worse survival than those without DM. Diabetes may be a predictive factor of survival in patients with PC. Surveillance of diabetes status and antidiabetes medication administration after the diagnosis of PC is of clinical importance.

Keywords: diabetes mellitus, pancreatic cancer, survival, meta-analysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]